Press Releases

07/20/2017 Kestrel Labs Receives Cavendish Impact Foundation Innovator Award

02/04/2017 Kestrel Labs, Inc. Awarded International Patent Coverage

06/07/2016 Kestrel Labs, Inc. Awarded Phase I SBIR Grant to Obtain Human Trials Data on Applications of Oximetry Technology to Respiratory Disease States

10/03/2015 Kestrel Labs, Inc. Co-Founder & CEO, Jonas Pologe Presents NICO at the 2015 I.A.M.P.O.V. Meeting in Tokyo

11/04/2014 Kestrel Labs, Inc. Awarded Phase II SBIR Grant to Obtain Human Trial Data on Extension of Advanced Oximetry Technology

03/17/2014 Kestrel Labs, Inc. Issued Two New Patents By The United States Patent and Trademark Office

09/10/2013 Kestrel Labs, Inc. Invited to Present at National Institutes of Health 2013 NHLBI Innovation Conference

10/01/2011 Kestrel Labs Awarded Grant for Extension of Advanced Oximetry Technology

03/15/2008 Kestrel Labs Second Highest Awardee in Colorado 2003-2007

7/01/2006 Kestrel Labs Awarded Phase II Renewal For Commercialization of Advanced Oximetry Technology

6/01/2005 Kestrel Labs Awarded Phase II Grant For Fetal Oximetry

12/17/2003 Kestrel Labs Awarded Two Additional SBIR Grants From the NIH

10/07/2003 Kestrel Labs CTO Invited Speaker at ASA 2003

04/14/2003 Kestrel Labs Receives Fast Track Phase I & Phase II SBIR Funding

 

Press Release 7/20/2017

KESTREL LABS, INC. PARTICIPATES AT CAVENDISH GLOBAL HEALTH IMPACT FORUM AND RECEIVES THE CAVENDISH IMPACT FOUNDATION INNOVATOR AWARD

Forum uniquely brings together leading family offices, foundations, and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and the life sciences

Boulder, Colorado July 20, 2017 — Kestrel Labs, Inc., a medical device company working on laser-based medical monitoring techniques that hold the promise of a new generation of monitoring devices, announced today that it presented at the Cavendish Global Health Impact Forum held July 18-20, 2017 at the University Club of Chicago in Chicago, IL, co-hosted with the Illinois Biotechnology Industry Organization (iBIO), PROPEL at the iBIO Institute, and the Innovation and New Ventures Office (INVO) at Northwestern University. Kestrel Labs was also one of two organizations to receive the inaugural Cavendish Impact Foundation Innovator Award.

The Forum provided an environment for family offices, foundations, and impact investors to develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcased presentations and panel discussions by leading family offices, accomplished foundations, impact investors, research institutions, private-sector companies, and nonprofit organizations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of impact investors, Cavendish Health Impact Forums are hosted by leading institutions around the world and take place four times each year.

Michael Moffat, Cavendish co-founder and Chairman explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Kestrel Labs’ research and development in the use of low-cost lasers in pulse oximetry positions them to make a major contribution to the field of noninvasive medical monitoring.”

“It was an honor to be selected to present at this unique event, as it is further confirmation that our innovative and groundbreaking improvements in the field of pulse oximetry will have a real impact on the lives of many patients by eliminating some of the most severe deficiencies that oximeters have had in their performance and accuracy that have not been addressed in the 35+ years since these monitors were first commercially launched,” said Jonas Pologe, Kestrel Labs CEO and co-founder. “We welcomed the chance to interact with this dynamic group of accomplished scientists, thought-leaders, and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world, and we are further honored to have our presentation recognized with the Cavendish Impact Foundation Innovator Award.

Cavendish Global consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides impact investors with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.

About the Cavendish Impact Foundation Innovator Award (“the Award”)
The Cavendish Impact Foundation Innovator Award is a grant presented to organizations demonstrating conspicuous attainment in the advancement of transformational innovations. Awards are granted to organizations presenting at Cavendish Global Health Impact Forums, where the audience consisting of single and multi-family offices, foundations, philanthropists, angel investors, impact investors, strategic partners, and fellow innovators, casts votes for the innovator that meets or exceeds the following benchmarks: highlighting an unmet need, clearly illustrating an innovative solution to the unmet need, and articulating the notable impact of the solution on patients around the world. Awards are provided through the generosity of the Foundation’s private community of donors.

About Kestrel Labs, Inc.
Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. Kestrel Labs' work focuses on extending photoplethysmography (the science behind pulse oximetry) to the measurement of additional blood analytes and hemodynamic parameters. This noninvasive and continuous medical monitoring technique holds the promise of a new generation of monitoring devices, helping to bring central laboratory analyzer functionality to the point of care, whether it be the hospital bedside, a physician's office, or settings outside the conventional healthcare environment. Please visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

About Cavendish Global
Cavendish Global is a peer-to-peer community of paradigm-changing innovators in health and the life sciences; over 200 leading family offices, philanthropists, foundations and impact investors; key opinion leaders and renown institutional partners that share a passion for well-conceived impact investing, sustainable philanthropy and delivering transformative impact. Cavendish provides the resources for innovators to advance their impactful work from mind to marketplace — through connectivity, advisory services, access to key opinion leaders, and capital opportunities. Together, the Cavendish community bridges the gaps and accelerates innovation. The most recent Health Impact Forum was held July 18-20, 2017 at the University Club of Chicago. For more information go to http://CavendishGlobal.com.

For Further Information, Contact: Ian Kenyon
Director, Corporate Communications
Cavendish Global
Ian.Kenyon@CavendishGlobal.com

Contact:
Ted Delianides
Kestrel Labs, Inc.
303.544.0660


(Return to Top of Page)

 

Press Release 2/4/2017

KESTREL LABS, INC. AWARDED INTERNATIONAL PATENT COVERAGE


Boulder, Colorado, 4 February 2017 - Kestrel Labs, Inc., a Colorado-based medical device company dedicated to advancing the state-of-the-art of pulse oximetry, announced that the Company has been awarded National Validation of European Patent No. 2706915.

EP2706915 has been nationalized in France, Germany, and the United Kingdom, which provides international coverage of this key technology and significantly expands the Company’s intellectual property portfolio. This patent covers a crucial element in the successful design and implementation of laser-based photoplethysmographic technologies, and its award confirms the uniqueness of this important invention.

About Kestrel Labs, Inc.
Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. The management team at Kestrel Labs brings together over 50 years of innovation in the medical device industry and is uniquely qualified to accomplish the Company's goals. Please visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

Contact:
Ted Delianides
Kestrel Labs, Inc.
303.544.0660


(Return to Top of Page)

 

Press Release 6/7/2016

KESTREL LABS, INC. AWARDED PHASE I SBIR GRANT TO OBTAIN HUMAN TRIALS DATA ON APPLICATIONS OF OXIMETRY TECHNOLOGY TO RESPIRATORY DISEASE STATES


Boulder, Colorado, 7 June 2016 - Kestrel Labs, Inc. announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) Grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).

The grant award will be used to explore whether information pertaining to the extent of upper airway obstruction is contained in the raw photoplethysmographic data and whether these data can be extracted and processed to provide an accurate, noninvasive, real-time measurement of the severity of this disease state. The proposed work has the ultimate goal of adding this measurement capability to the existing Kestrel Labs NiCO™ monitoring technology.

Successful completion of this research will offer a strong proof-of-principle and hopefully lead to the creation of the first commercial monitor to allow noninvasive real-time measurement of this critical parameter.

About Kestrel Labs, Inc.
Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. The Company's core technology is based on the concept of "laser-based" pulse oximetry. Kestrel Labs has developed proprietary technology that allows the point-source and narrow-bandwidth advantages of laser diode light sources to be used for the measurement of a number of additional blood analytes with unprecedented accuracy that does not appear attainable with conventional, LED-based technologies. Visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

Contact:
Ted Delianides
Kestrel Labs, Inc.
303.544.0660


(Return to Top of Page)

 

Press Release 10/3/2015

KESTREL LABS, INC. CO-FOUNDER & CEO, JONAS POLOGE PRESENTS NiCO™ AT THE 2015 I.A.M.P.O.V. MEETING IN TOKYO


Boulder, Colorado, 3 October 2015 - Kestrel Labs, Inc., a Colorado-based medical device company dedicated to advancing the state-of-the-art of pulse oximetry, announced that its CEO, Jonas Pologe, was an invited speaker at the 2015 Innovations and Applications of Monitoring Perfusion, Oxygenation and Ventilation (IAMPOV) meeting in Tokyo, Japan. IAMPOV is a unique gathering of the top scientists and researchers in the fields of pulse oximetry.

As one of the inventors on some of the first commercially-viable pulse oximeters manufactured by BIOX Technology in the early 1980s, and, more recently, one of the principal inventors of laser-based pulse oximetry, Mr. Pologe was invited to present at this Who’s Who of pulse oximetry meeting along with a host of other key scientists in this field. For the first time, in a public forum, Mr. Pologe presented performance data from Kestrel Labs’ laser-based NiCO™ pulse oximeter showing unprecedented measurement accuracy and precision of all four primary species of hemoglobin.

A poster showing the full list of lecturers invited to speak at this conference can be accessed by clicking on the thumbnail of the poster here:



About Kestrel Labs, Inc.
Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. The management team at Kestrel Labs brings together over 50 years of innovation in the medical device industry and is uniquely qualified to accomplish the Company's goals. Please visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

Contact:
Ted Delianides
Kestrel Labs, Inc.
303.544.0660


(Return to Top of Page)

 

Press Release 4/11/2014

KESTREL LABS, INC. AWARDED PHASE II SBIR GRANT TO OBTAIN HUMAN TRIAL DATA ON EXTENSION OF ADVANCED OXIMETRY TECHNOLOGY


Boulder, Colorado, 11 April 2014 - Kestrel Labs, Inc. announced today that it has been awarded a Phase II Small Business Innovation Research (SBIR) Grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The grant award will be used to continue research and development into the noninvasive measurement of an additional hemodynamic parameter. Reliable and accurate measurement of this important clinical parameter is commonly obtained via invasive blood sampling, but Kestrel Labs believes that with its proprietary laser-based technology it should be possible to obtain an accurate measurement noninvasively.

This work is a continuation of the successful Phase I studies and will build on that research as well as provide the first in vivo calibration data. Successful completion of this research will offer a strong proof-of-principle and hopefully lead to the creation of a commercial monitor that makes clinically-accurate noninvasive real-time measurements of this critical parameter.

For more details on this research, contact Kestrel Labs directly.

About Kestrel Labs, Inc.
Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. The Company's core technology is based on the concept of "laser-based" pulse oximetry. Kestrel Labs has developed proprietary technology that allows the point-source and narrow-bandwidth advantages of laser diode light sources to be used for the measurement of a number of additional blood analytes with unprecedented accuracy that does not appear attainable with conventional, LED-based technologies. Visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

Contact:
Ted Delianides
Kestrel Labs, Inc.
303.544.0660


(Return to Top of Page)

 

Press Release 03/17/2014

KESTREL LABS, INC. ISSUED TWO NEW PATENTS BY THE UNITED STATES PATENT AND TRADEMARK OFFICE


Boulder, Colorado, 17 March 2014 – Kestrel Labs, Inc., a Colorado-based medical device company dedicated to advancing the science of pulse oximetry, announced today the issuance of two new patents by the U.S. Patent and Trademark Office.

“U.S. Patents 8,498,507 and 8,632,262 cover opto-mechanical aspects of our Company’s novel approach to pulse oximetry,” stated Jonas A. Pologe, CEO and Chief Technology Officer of Kestrel Labs, who is also a co-inventor on both patents. “The successful use of laser light for photoplethysmographic measurements is a major advancement in the field of pulse oximetry. Using laser light sources instead of conventional LEDs greatly expands the measurement capabilities and improves the accuracy of a new generation of pulse oximeters. These two new patents increase the breadth and extend the lifetime of Kestrel Labs’ intellectual property portfolio by protecting key implementation elements of our core technology.”

An aggressive intellectual property strategy is central to Kestrel Labs’ technology and product development program. The Company has already received patents on its core technology and has additional domestic and international patent applications pending review.

About Kestrel Labs, Inc.
Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. Kestrel Labs' internal work focuses on extending photoplethysmography (the science behind pulse oximetry) to the measurement of additional blood analytes and hemodynamic parameters. This noninvasive and continuous medical monitoring technique holds the promise of a new generation of diagnostic devices, helping to bring central laboratory analyzer functionality to the point of care, whether it be the hospital bedside, a physician's office, or settings outside the conventional healthcare environment. Please visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

Contact:
Ted Delianides
Kestrel Labs, Inc.
303.544.0660


(Return to Top of Page)

 

Press Release 08/07/13

KESTREL LABS, INC. INVITED TO PRESENT AT NATIONAL INSTITUTES OF HEALTH 2013 NHLBI INNOVATION CONFERENCE

Boulder, Colorado, 07 August 2013 – Kestrel Labs, Inc., a Colorado-based medical device company dedicated to advancing the science of pulse oximetry, announced today that it has been selected as one of only 6 companies to present at the 2013 NHLBI Innovation Conference that will be held in San Francisco, CA on September 10, 2013. Ted P. Delianides, Ph.D. will present the status of the Company’s product development and its ground-breaking work in laser-based pulse oximetry.

About NHLBI and the 2013 Regional Innovation Conference
Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at http://www.nhlbi.nih.gov. The NHLBI 2013 Regional Innovation Conference will bring together small businesses, angel investors, venture capitalists, strategic partners, and business leaders from the biotech and pharmaceutical industries. The conference will feature presentations by top NHLBI SBIR-funded companies with innovative technologies on the brink of commercialization, an expert panel of investors, and opportunities for partnering and networking.

About Kestrel Labs, Inc.
Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. Kestrel Labs' internal work focuses on extending photoplethysmography (the science behind pulse oximetry) to the measurement of additional blood analytes and hemodynamic parameters. This noninvasive and continuous medical monitoring technique holds the promise of a new generation of diagnostic devices, helping to bring central laboratory analyzer functionality to the point of care, whether it be the hospital bedside, a physician's office, or settings outside the conventional healthcare environment. Please visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

Contact:
Kestrel Labs, Inc.
Ted Delianides, Ph.D.
Chief Operating Officer
303.544.0660


(Return to Top of Page)

 

Press Release 10/1/2011

KESTREL LABS, INC. AWARDED SMALL BUSINESS GRANT FROM THE NATIONAL INSTITUTES OF HEALTH

SBIR Phase I Grant to Support Extension of Advanced Pulse Oximetry Technology


Boulder, Colorado, 01 October 2011 - Kestrel Labs, Inc., an emerging leader in the field of non-invasive medical monitoring, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) Grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The grant award will be used to extend the Company's Advanced Oximetry Technology to the noninvasive measurement of additional blood parameters.

About Kestrel Labs, Inc.
Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. The Company's core technology is based on the concept of "laser-based" pulse oximetry. Kestrel Labs has developed proprietary technology that allows the point-source and narrow-bandwidth advantages of laser diode light sources to be used for the measurement of a number of additional blood analytes with unprecedented accuracy that does not appear attainable with conventional, LED-based technologies. Visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

Contact:
Ted Delianides
Kestrel Labs, Inc.
303.544.0660


(Return to Top of Page)

 

Press Release 3/15/2008

KESTREL LABS, INC. SECOND HIGHEST COLORADO AWARDEE OF SBIR GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH

Boulder, Colorado, 15 March 2008 - Kestrel Labs, Inc., an emerging leader in the field of non-invasive medical monitoring, announced today that for fiscal years 2003 through 2007 the Company was the second-highest awardee in the State of Colorado of research funds through the Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH).

This statistic was revealed in a presentation entitled "Secrets of NIH SBIR & STTR Grant Applications" given by Dr. Gregory Milman of the National Institute of Allergies and Infectious Diseases (NIAID). The talk was part of the Colorado BioScience Association (CBSA) seminar "NIH SBIR/STTR Funding" held on March 6, 2008 at the Fitzsimons Bioscience Park Center in Aurora, Colorado.

About Kestrel Labs, Inc.
Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. The Company's core technology is based on the concept of "laser-based" pulse oximetry. Kestrel Labs has developed proprietary technology that allows the point-source and narrow-bandwidth advantages of laser diode light sources to be used for the measurement of a number of additional blood analytes with unprecedented accuracy that does not appear attainable with conventional, LED-based technologies. Visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

Contact:
Ted Delianides
Kestrel Labs, Inc.
303.544.0660


(Return to Top of Page)

 

Press Release 7/1/2006

KESTREL LABS, INC. AWARDED SMALL BUSINESS GRANT FROM THE NATIONAL INSTITUTES OF HEALTH

SBIR Phase II Renewal Grant to Support Development of Advanced Oximetry Technology


Boulder, Colorado, 01 July 2006 - Kestrel Labs, Inc., an emerging leader in the field of non-invasive medical monitoring, announced today that it has been awarded a Phase II Renewal Small Business Innovation Research (SBIR) Grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The three-year grant award will support development work of the Company's Advanced Oximetry Technology.

The Company's core technology is based on the concept of "laser-based" pulse oximetry. Kestrel Labs has developed proprietary technology that allows the point-source and narrow-bandwidth advantages of laser diode light sources to be used for the measurement of a number of additional blood analytes providing unprecedented measurement accuracy that does not appear attainable with conventional, LED-based technologies.

"Our Phase I and II research work resulted in a prototype system that far exceeded our expectations in both performance and accuracy," said Jonas Pologe, Kestrel Labs' Chief Executive Officer, who is the Principal Investigator on the grant. "The follow-on work will further our product development goals of a market-ready device with FDA 510(k) clearance for its sale to the medical community."

The latest grant award is the fifth that the Company has received through the SBIR program of the National Institutes of Health. "We are thrilled that the researchers associated with NIH continue to see the scientific and clinical value of our projects and recognize the significant progress we continue to make," stated Ted Delianides, the Company's Chief Operating Officer and Grants Management Coordinator. "The level of technical, business, and market scrutiny encountered during the peer-review process is an important and welcome validation of the efforts made by our team."

About Kestrel Labs, Inc.
Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. Please visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

Contact:
Ted Delianides
Kestrel Labs, Inc.
303.544.0660


(Return to Top of Page)

 

Press Release 6/1/2005

KESTREL LABS, INC. AWARDED PHASE II SBIR GRANT FROM THE NATIONAL INSTITUTES OF HEALTH

Research Grant to Support Development of Fetal Oximetry Technology


Boulder, Colorado, 01 June 2005 - Kestrel Labs, Inc. announced today that it has been awarded a Phase II Small Business Innovation Research (SBIR) Grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The grant award will support development work of the Company's Fetal Oximetry Sensor Technology.

Fetal oximetry is the measurement of oxygen status of the fetus during labor and delivery and is seen as one of the keys to improving neonatal outcomes. In the entire U.S. hospital healthcare system, four of the top ten most expensive conditions requiring hospitalization are related to the care of infants. One of these four is "lack of oxygen in utero," also termed birth asphyxia, which requires an average stay of almost 13 days at a cost of nearly $40,000. Kestrel Labs believes that accurate fetal oximetry could potentially provide direct monitoring for birth asphyxia and also help reduce the rapidly increasing rate of cesarean sections in the United States, and that eliminating unnecessary C-sections could potentially save the U.S. health care industry over one billion dollars annually.

About Kestrel Labs, Inc.
Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. Please visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

Contact:
Ted Delianides
Kestrel Labs, Inc.
303.544.0660


(Return to Top of Page)

 

Press Release 12/17/2003

KESTREL LABS, INC. AWARDED TWO ADDITIONAL SBIR GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH

Phase I Grant to Study Fetal Oximetry; Phase II Grant for Advanced Oximetry


Boulder, Colorado, 17 December 2003 - Kestrel Labs, Inc., a Colorado-based medical device company dedicated to advancing the state-of-the-art of pulse oximetry, announced the following today: The Company has been awarded a Phase I Small Business Innovation Research (SBIR) Grant from the National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH). Additionally, the Company's previously-announced SBIR Phase I/II "Fast-Track" Grant, from the National Heart, Lung, and Blood Institute (NHLBI), to investigate advanced pulse oximetry has successfully moved into Phase II, bringing total support to date for this important work to nearly $1,000,000.

"Being able to conclusively attain a proof of principle of our advanced oximetry technology during the short time period supported by our Phase I grant was quite encouraging," said Jonas Pologe, Kestrel Labs' Chief Technology Officer, who is the Principal Investigator on the grant. "With the significant increase in funding afforded by the Phase II award from NHLBI, we are looking forward to expanding our technical staff and completing the prototyping work for the next generation of pulse oximetry."

The Company's Phase I SBIR Grant from NICHD is in the field of fetal oximetry, which is the measurement of oxygen status of the fetus during labor and delivery. A Company representative stated, "Accurate fetal oximetry is seen as one of the keys to reducing the rapidly increasing rate of cesarean sections in the United States. Eliminating unnecessary C-sections could potentially save the U.S. health care industry over one billion dollars annually. The current solution for monitoring oxygen status of the fetus has met with mixed success in the marketplace, and the American College of Obstetricians and Gynecologists (ACOG) has chosen not to endorse it. We see our work leading to a practical, accurate fetal oximetry solution that is readily accepted in clinical practice."

Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. The management team at Kestrel Labs brings together over 45 years of innovation in the medical device industry and is uniquely qualified to accomplish the Company's goals.

Please visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

Contact:
Ted Delianides
Kestrel Labs, Inc.
303.544.0660


(Return to Top of Page)

 

Press Release 10/7/2003

KESTREL LABS, INC. CO-FOUNDER AND CHIEF TECHNOLOGY OFFICER INVITED TO PRESENT PAPER AT 2003 ASA CONFERENCE AND PARTICIPATE ON PANEL ON FUTURE OF OXIMETRY


Boulder, Colorado, 07 October 2003 - Kestrel Labs, Inc., a Colorado-based medical device company dedicated to advancing the state-of-the-art of pulse oximetry, announced today that its Chief Technology Officer, Jonas Pologe, has been invited along with other scientists, medical doctors, and engineers to present a paper and participate in the panel "Pulse Oximetry Meets the Press: Point and Counterpoint" at the 2003 American Society of Anesthesiologists Annual Meeting held October 11-15, 2003 in San Francisco, CA.

The panel will be sponsored by the Society for Technology in Anesthesia. The papers presented by the panel participants will be published online on the GASNet site at http://www.gasnet.org/pomtp/ as part of a new Pulse Oximetry Guidebook. Mr. Pologe's paper, entitled "Pulse Oximetry - Where it came from and where it is going" discusses the still brief history of pulse oximetry and explores its potential as a monitoring modality once clinicians and device developers gain the same level of experience with it that they have had with other vital signs monitors.

The full text of Mr. Pologe's paper can be accessed at www.gasnet.org/pomtp/pologe.php. [Article currently available at: GASNet Article]

About the Society for Technology in Anesthesia
The Society for Technology in Anesthesia (STA) is an international organization of physicians, engineers, students and others with an interest in anesthesia-related technologies. The Society's mission is to improve the quality of patient care by improving technology and its application. You can find STA on the web at www.anestech.org/.

About GASNet
Founded in 1993, GASNet, the "Global Anesthesia Server NETwork," was one of the first 500 Web sites on the Internet, and the first Web site devoted to anesthesiologists. Established by physicians to create a global health care forum, GASNet has been an enduring success. GASNet has developed a careful yet innovative approach to information sharing, providing credible, interactive, multimedia content to users from more than 100 countries. You can find GASNet on the web at www.GASNet.org.

About Kestrel Labs, Inc.
Kestrel Labs, Inc. is a medical device company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. The management team at Kestrel Labs brings together over 45 years of innovation in the medical device industry and is uniquely qualified to accomplish the Company's goals. Please visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.


Contacts:

Kestrel Labs, Inc.
Ted Delianides, Ph.D.
303.544.0660

GASNet
Charlotte Bell, M.D.
203.785.4900
Society for Technology in Anesthesia
Beverlee Anderson
505.983.4923


(Return to Top of Page)

 

Press Release 4/14/2003

KESTREL LABS, INC. AWARDED FAST-TRACK SBIR GRANT FROM NATIONAL INSTITUTES OF HEALTH

$850,000 Grant to Study Advanced Pulse Oximetry Technologies


Boulder, Colorado, 14 April 2003 - Kestrel Labs, Inc., a Colorado-based medical device company dedicated to advancing the state-of-the-art of pulse oximetry, announced today that it has received a Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). This grant is a combined SBIR Phase I/II "Fast-Track" award of approximately $850,000 to investigate advanced pulse oximetry technologies.

"We are extremely pleased that the peer reviewers at NIH recognized the significant need for our technology in the clinical community. The fact that they chose Kestrel Labs for a fast-track award, which typically go to fewer than 5% of all Phase I awardees, is a testament to the importance of the work as well as the strength of the team we have assembled," said Jonas Pologe, Kestrel Labs' Chief Technology Officer, who will serve as Principal Investigator on the grant.

"The pulse oximeter has been an important tool for clinical diagnosis since its commercial launch over 20 years ago. It has given clinicians a `fifth' vital sign, joining heart rate, respiratory rate, blood pressure, and body temperature as the primary indicators of a patient's health," added Ted Delianides, Vice President of Engineering. "Our work at Kestrel Labs will address one of the major shortcomings of conventional pulse oximetry. It will lead to products that significantly outperform the installed base of roughly 1,000,000 pulse oximeters in use worldwide.

Kestrel Labs, Inc. is a medical electronics company focused on the research, development, and commercialization of valuable, new, and innovative medical technologies. The Kestrel Labs' team brings together over 45 years of innovation in the medical device industry and is uniquely qualified to accomplish the company's goals. Please visit Kestrel Labs, Inc. on the web at www.KestrelLabs.com.

Contact:
Ted Delianides
Kestrel Labs, Inc.
303-544-0660


(Return to Top of Page)